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Background: Myocardial ischemia is the most common cause of congestive heart
failure. Angiogenic therapy has recently been demonstrated to enhance myocardial
perfusion in the ischemic setting. We therefore hypothesized that administration of
adenovirus encoding for vascular endothelial growth factor could be used to en-
hance myocardial function in a pacing-induced model of heart failure.
Methods: Yorkshire swine underwent a left thoracotomy with placement of a
ventricular epicardial pacing system. Animals received adenovirus coding either for
the 121-amino-acid isoform of vascular endothelial growth factor (AdCUVEGF121.1
group, n  8) or a null vector coding for no genes (AdNull group, n  8). The
adenovirus was administered in the left ventricular free wall as 10 transepicardial
injections of 100 L each (total dose of 1011 particle units). After a 1-week recovery
period, animals were paced at a rate of 230 beats/min for 7 days to induce heart
failure. Transthoracic echocardiographic and sonomicrometric measurements were
performed before pacing (baseline), on termination of pacing (day 0), and then
weekly for 3 weeks.
Results: The fractional area change was significantly decreased in AdNull animals
at day 0 after pacing compared with the AdCUVEGF121.1 animals (29%  14% vs
46% 8%, P .02). The fractional area change recovered to baseline values within
7 days in the AdCUVEGF121.1 animals (62%  7%) but remained significantly
impaired in the AdNull group compared with that in the AdCUVEGF121.1 animals
up to day 21 (P  .04). Similarly, fractional wall thickening demonstrated a
decrease at day 0 after pacing that was greater (P  .05) in the AdNull group
compared with that in the AdCUVEGF121.1 group in 5 of 6 segments. Fractional
wall thickening returned to levels approximating prepacing values in all segments
within 7 days in the AdCUVEGF121.1 group but remained significantly impaired
compared with prepacing fractional wall thickening (P  .05) in the AdNull group
in 5 of 6 segments up to day 21 after pacing. Segmental shortening, as measured by
sonomicrometry, also was significantly decreased at day 7 in the AdNull group
compared with that in the AdCUVEGF121.1 group (10%  4% vs 16%  3%, P 
.004) and remained significantly impaired (P  .05) in the AdNull group at day 14
and 21 when compared with baseline values.
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Conclusion: Preservation of cardiac performance and a more rapid recovery of
myocardial function can be achieved in a model of pacing-induced cardiomyopathy
with adenovirus-mediated administration of vascular endothelial growth factor
compared with that seen in a null virus control group. These data suggest that
angiogenic therapy may be useful clinically in treating cardiomyopathy.
Coronary artery disease remains the leadingcause of death in the United States today.1In patients with coronary disease, the lead-ing cause of death is congestive heart fail-ure.2,3 In turn, the leading cause of conges-tive heart failure is myocardial ischemia.
Heart failure caused by myocardial ischemia is typically
associated with the occurrence of hibernating myocardium,
viable tissue that is nevertheless poorly functioning or non-
contractile because of severe ischemia.4-6 It is thought that
this phenomenon serves as a protective mechanism, down-
regulating energy consumption to preserve cell viability. By
definition, however, myocardial hibernation and restoration
of myocardial function is reversible with myocardial reper-
fusion.
Although myocardial ischemia caused by discrete coro-
nary stenosis can usually be treated with coronary angio-
plasty or bypass graft surgery, diffuse coronary artery dis-
ease is commonly not amenable to these conventional
therapies. On the basis of these considerations, we hypoth-
esized that improvement in blood flow to the myocardium
induced by treatment with angiogenic factors could be used
to improve myocardial dysfunction in the setting of isch-
emic cardiomyopathy.
Vascular endothelial growth factor (VEGF) is a ho-
modimeric 34- to 44-kd heparin-binding glycoprotein that is
a potent angiogenic growth factor (angiogen). As a result of
posttranscriptional mRNA splicing, VEGF normally exists
as 4 major isoforms of 121-, 165-, 189-, and 206-amino-acid
residues.7 VEGF is an attractive candidate for therapeutic
angiogenic applications in that, because of localization of its
receptors almost exclusively to vascular endothelial cells, it
is one of the most specific of the known angiogens.
We and others have used gene transfer as a delivery
strategy in which the coding sequence for a selected
angiogen, such as VEGF, is delivered to the target tissue
to induce angiogenesis.8-12 Although encouraging initial
data have demonstrated improvement in regional myo-
cardial function in the setting of discrete coronary ob-
structions with this therapy,8-10 the efficacy of angiogenic
therapy in reversing global myocardial dysfunction is
largely unknown.
In the present study we compared the efficacy of in-
tramyocardial administration of an adenovirus coding for
the 121-amino-acid isoform of VEGF (AdCUVEGF121.1)
with that of a vector coding for no genes (AdNull) in
enhancing myocardial function in a porcine pacing model of
cardiomyopathy. Data generated in this study suggest that
AdCUVEGF121.1 administration helps to preserve and en-
hance recovery of cardiac function in this model of ischemic
cardiomyopathy. This may represent a novel strategy for
treating cardiomyopathy in the ischemic setting.
Methods
Experimental Model for Heart Failure
A model of cardiomyopathy was created in male Yorkshire swine
(25-30 kg) by using rapid ventricular pacing.13,14 Care provided
for animals was in compliance with the US National Research
Council’s “Guide for the Care and Use of Laboratory Animals”
and proceeded under protocols approval by the Evanston North-
western Healthcare Institutional Animal Care Committee. Initial
anesthesia was performed with telazol (4 mg/kg) and xylazine (2
mg/kg) and maintained with isoflurane (0.5%-2.0%) after intuba-
tion. A posterolateral thoracotomy was performed, and 2-mm
piezoelectric crystals (Sonometrics, London, Ontario, Canada)
were implanted in the myocardium at the apex and at the base of
the left ventricle under the left atrial appendage (for long-axis
measurements) and anteriorly and posteriorly at the midpapillary
level (for short-axis measurements).
After initial testing of data acquisition and analysis with the
Digital Ultrasonic Measurement System and the Sonosoft software
program 3.1 (Sonometrics), the sonomicrometry leads were exte-
riorized for later use. An epicardial pacing lead (Medtronic, Min-
neapolis, Minn) was placed at the left ventricular apex and at-
tached to a single-chamber pacing generator (Medtronic), which
was placed subcutaneously. After a 7-day recovery period, pacing
at 230 beats/min was initiated and continued for 7 days. Pacing
was well tolerated in all animals. (There were 2 deaths each in the
AdNull and the AdCUVEGF121.1 groups: one before and one
immediately after pacing in the AdCUVEGF121.1 group and both
immediately after pacing in the AdNull group.)
Echocardiographic and sonomicrometric data were collected at
the time of the operation, immediately before pacing (baseline; 7
days postoperatively), immediately after pacing (day 0; 14 days
postoperatively), and weekly thereafter for 3 weeks before the
animals were killed (days 7, 14, and 21). All echocardiographic
and sonomicrometric data were recorded for subsequent analysis,
except for some instances in which results were uninterpretable or
unavailable because of poor image quality or lead displacement,
respectively.
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Adenovirus Vectors
The replication-deficient vector AdCUVEGF121.1 is an E1a–, par-
tial E1b–, partial E3– adenovirus vector based on human adenovi-
rus 5 into which an expression cassette is inserted into the E1
region containing the cytomegalovirus immediate early promoter-
enhancer, an artificial splice sequence, the human VEGF 121
cDNA, and the SV40 polyA/stop signal.15 The vector AdNull
(containing no transgene) served as the control. AdCUVEGF121.1-
induced VEGF expression was confirmed by means of enzyme-
linked immunosorbent assay (R&D Systems Inc, Minneapolis,
Minn) assessment of tissue-culture supernatant 48 hours after in
vitro infection of A549 (American Type Culture Collection, Rock-
ville, Md).
Intramyocardial Vector Delivery
In initial experiments naive animals undergoing crystal placement
and pacing, as described above, but without vector injection, were
analyzed to assess the specific effects of pacing alone on ventric-
ular function (n  5). Subsequently, at the time of the initial
operation, animals were administered either AdCUVEGF121.1
(n  8) or the control vector AdNull (n  8) by means of direct
myocardial injection of the vector in phosphate-buffered saline
solution at 10 sites (10 L/site) placed at 1-cm intervals in the
anterior and lateral territory of the left ventricle (total dose, 1011
pu).
Echocardiographic Assessment
Two-dimensional transthoracic images were obtained with an
Acuson echocardiographic machine (128 XP/10; Acuson, Moun-
tain View, Calif) and a 3.0/3.5-MHz dual-frequency transducer
(Acuson S 3194). During each examination, animals were sedated
and placed in the left lateral decubitus position, and right paraster-
nal short-axis midpapillary views of the left ventricle were ob-
tained at rest. Images were recorded for 3 minutes on a standard
VHS videotape. Offline analysis of the data was performed by a
single experienced investigator, who was blinded to group assign-
ment, using the Image Vue DCR 1.50 System (Nova Microsonics,
Mahwah, NJ).
Global ventricular function was estimated by calculating the
fractional area change (FAC) of the left ventricle. The percentage
of FAC has been shown to correlate well with radionuclide and
angiography measurements of ejection fraction.16 The percentage
of FAC was measured by tracing the end-diastolic area (EDA) and
the end-systolic area (ESA) of the ventricle from the midpapillary
short-axis view. The percentage of FAC was then calculated by
using the following equation:
% FAC  [(EDA – ESA)/EDA]  100.
Regional wall-motion function was evaluated by dividing the left
ventricle into 6 equal 60° radial segments (Figure 1). Mean systolic
and mean diastolic wall thickness were calculated by averaging 3
single measurements in each segment.
Systolic wall thickening in each segment was defined as the
mean systolic wall thickness minus the mean diastolic wall thick-
ness. Fractional wall thickening (FWT) was defined as the mean
systolic wall thickening times 100 divided by the mean diastolic
wall thickness.
Sonomicrometric Assessment
Heart rate, segmental shortening, stroke volume, and cardiac out-
put were measured with a commercial digital sonomicrometry
system (Sonometrics Corp, London), according to the manufactur-
er’s specifications, before (rest) and after (stress) administration of
epinephrine (10 g administered intravenously) at each hemody-
namic measurement time point.17 The scalar distances between
omnidirectional sonomicrometers (pairs of 1.3-MHz piezoelectric
crystals) were recorded simultaneously at a sampling frequency of
greater than 240 Hz. Parameters derived from the intercrystal
distances and heart rate were calculated by using a 4-component
system consisting of (1) a 486-class personal computer that con-
trols sonomicrometry functions and runs application software, (2)
a customized timing board that controls the length of the energiz-
ing pulse and the sequence of transducer transmissions, (3) a
customized distance-measuring circuit that translates the ultrasonic
signal into a distance measurement, and (4) an 8-channel analog-
to-digital board that is synchronized with the sonomicrometer
distance measurements.
Statistical Analysis
Data are reported as means and SDs, and significance measure-
ments were calculated with paired or unpaired Student t tests, as
appropriate.
Results
Pacing Model
In initial experiments conducted in naive animals without
vector administration, pacing results in a decrease in ven-
tricular function that persisted up to 21 days after cessation
of pacing. Segmental shortening, for example, decreased
from 13.5%  4.6% before pacing to 5.6%  3.0% at day
0 after pacing and 6.8%  3.0% at day 7 after pacing (P 
Figure 1. Schematic of ventricular sectioning in the short axis at
the midventricular (midpapillary) level for echocardiographic
analysis of FWT.
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Figure 2. Echocardiographic assessment of the percentage of FAC of the left ventricular cavity (systole vs diastole)
in the short axis at the midventricular (midpapillary) level calculated as described in the “Methods” section
(mean  SD). S, Initial operation; BP, before pacing; 0, 7, 14, and 21, days after cessation of pacing. Statistical
comparisons between AdCUVEGF121.1 and AdNull groups are provided above the corresponding time point.
Statistically significant comparisons for AdNull at various time points and at baseline (BP) are provided as
indicated (*P < .05, **P < .01).
Figure 3. Echocardiographic assessment of the percentage of FAC of the left ventricular cavity (systole vs diastole)
in the short axis at the midventricular (midpapillary) level calculated as the percentage of change (mean  SD)
of each animal from its corresponding prepacing baseline value, as described in the “Methods” section. BP, Before
pacing; 0, 7, 14, and 21, days after cessation of pacing. Statistical comparisons between the AdCUVEGF121.1 and
AdNull groups are provided above the corresponding time point. Statistically significant comparisons for AdNull
at various time points and at baseline (BP) are provided as indicated (*P < .05, **P < .01).
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Figure 4. Sonomicrometric assessment of ventricular function. All analyses are based on measurements with
piezoelectric crystals of short- and long-axis dimensions in systole versus diastole calculated as described in the
“Methods” section. Depicted are absolute values and percentage changes from the prepacing baseline value of
each animal (mean SD), respectively, in short-axis segmental shortening (A and B), stroke volume (C and D), and
cardiac output (E and F). S, Initial operation; BP, before pacing; 0, 7, 14, and 21, days after cessation of pacing.
Values are AdCUVEGF121.1 (open circles) versus AdNull (filled circles). Statistical comparisons between AdCU-
VEGF121.1 and AdNull groups are provided above the corresponding time point. Statistically significant compar-
isons for AdNull at various time points and at baseline (BP) are provided as indicated (*P < .05, **P < .01).
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.03) and remained decreased at 9.8%  5.8% up to 21 days
after pacing.
Echocardiographic assessment of ventricular morphol-
ogy in the treated animals at day 21 after pacing also
demonstrated evidence consistent with the presence of con-
gestive failure. For example, end-diastolic area in the
AdCUVEGF121.1 animals was 910  200 mm2 versus
1120  230 mm2 in the AdNull group. End-systolic areas
were 350  110 mm2 and 560  180 mm2, respectively.
Echocardiographic Assessment of Global Ventricular
Function
Echocardiographic assessment of FAC at the midventricular
level did not differ between the AdCUVEGF121.1 and
Figure 4. Cont’d.
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AdNull groups before initiation of pacing (67%  5% vs
66%  4%, P  .9; Figure 2). FAC significantly decreased
on termination of pacing in both groups but was signifi-
cantly greater in the AdCUVEGF121.1 group compared with
that in the AdNull group at this time point (46%  8% vs
29%  14%, P  .02). Ventricular function improved in
both groups over succeeding time points, but although the
FAC in the AdCUVEGF121.1 group recovered to levels
approximating prepacing values by day 7 after pacing, FAC
in the AdNull group remained significantly decreased com-
pared with AdCUVEGF121.1 levels throughout the 3-week
period (day 7: 48%  14% vs 62%  7%, P  .04; day 21:
52%  13% vs 65%  5%, P  .04).
The differences between the AdCUVEGF121.1 and
Figure 4. Cont’d.
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Figure 5. Sonomicrometry assessment of ventricular function after administration of epinephrine. All analyses are
based on measurements from piezoelectric crystals measuring short- and long-axis dimensions in systole versus
diastole calculated as described in the “Methods” section. Depicted are absolute values and percentage changes
from the prepacing baseline value of each animal (mean  SD), respectively, in short-axis segmental shortening
(A and B), stroke volume (C and D), and cardiac output (E and F). S, Initial operation; BP, before pacing; 0, 7, 14,
and 21, days after cessation of pacing. Values are AdCUVEGF121.1 (open circles) versus AdNull (filled circles).
Statistical comparisons between AdCUVEGF121.1 and AdNull groups are provided above the corresponding time
point. Statistically significant comparisons for AdNull at various time points and at baseline (BP) are provided as
indicated (*P < .05, **P < .01).
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AdNull groups were more pronounced if changes in FAC
were plotted as a function of change from each animal’s
own prepacing baseline measurements (Figure 3). For ex-
ample, by using this analysis, the AdCUVEGF121.1 animals
demonstrated a decrease in FAC of no more than about 7%
at any time point at or beyond 7 days after pacing compared
with prepacing values, whereas AdNull animals demon-
strated a decrease from baseline in FAC that was 22% 
16% at 21 days after pacing (P  .02).
Echocardiographic Assessment of FWT
FWT was similar in all 6 midventricular segments in both
the AdCUVEGF121.1 and AdNull groups before pacing
(AdCUVEGF121.1 vs AdNull: 37%  6% vs 39%  5%
Figure 5. Cont’d.
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[mean of all segments]) but demonstrated a decrease at day
0 after pacing that was greater (P  .05) in the AdNull
group compared with that in the AdCUVEGF121.1 group in
5 of 6 segments. The average FWT for all segments im-
proved to 36%  5% within 7 days after pacing in the
AdCUVEGF121.1 group, approximating prepacing levels,
but remained significantly impaired (P .04) compared
with prepacing FWT in the AdNull group in 5 of 6 seg-
ments, even at day 21.
Sonomicrometric Assessment of Hemodynamic
Performance
The prepacing values for segmental shortening did not
differ significantly between the AdCUVEGF121.1 and the
Figure 5. Cont’d.
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AdNull groups (Figure 4, A). Segmental shortening was not
significantly impaired in the AdCUVEGF121.1 group at any
time after pacing compared with the prepacing values. In
contrast, segmental shortening at day 7 was significantly
decreased in the AdNull group compared with that in the
AdCUVEGF121.1 group (10%  4% vs 16%  3%, P 
.004) and remained significantly impaired (P  .05) in the
AdNull group at day 14 and 21 when compared with base-
line values. These differences were more dramatically dem-
onstrated when the postpacing function of each animal was
expressed as a percentage change from its own baseline
(immediate prepacing) values (Figure 4, B).
Stroke volume was also equivalent in the
AdCUVEGF121.1 group compared with that in the AdNull
animals before pacing and did not significantly decrease
from these baseline values in the AdCUVEGF121.1 group at
any time during the postpacing study period (Figure 4, C).
In contrast, stroke volume in the AdNull group became
significantly more impaired throughout the postpacing pe-
riod (day 21: P  .02). Depression of stroke volume was
most pronounced compared with corresponding values for
the AdCUVEGF121.1 group at day 7 after pacing (19 4 vs
37  12 mL, P  .004) but was also impaired as compared
with that of the AdCUVEGF121.1 animals at day 14 (15 
5 vs 31  10 mL, P  .02) and at day 21 (13  5 vs 32 
12 mL, P .04). This impairment in ventricular function in
AdNull animals was also demonstrated when comparing the
postpacing results of each animal with its corresponding
baseline value (Figure 4, D).
Cardiac outputs were similar for the 2 groups immedi-
ately before pacing, although they were greater for the
AdCUVEGF121.1 animals compared with those seen in the
AdNull animals at the time of the initial operation (Figure 4,
E). Cardiac outputs were well preserved in the
AdCUVEGF121.1 group compared with those in the AdNull
group throughout the study (day 7: 4.3  1.1 vs 2.7  0.7
L/min, P .009; day 14: 3.8 1.1 vs 1.8 0.3 L/min, P
.004; day 21: 3.3  1.1 vs 1.0  0.3 L/min, P  .02). Even
at day 21 after pacing, cardiac output in the AdNull group
remained significantly impaired (P  .03) when compared
with each animal’s own baseline values (Figure 4, F).
Assessment of Ventricular Performance With
Pharmacologic Stress
Sonomicrometry was used to assess the effect of epineph-
rine administration (10 g administered intravenously) on
cardiac performance (Figure 5, A-F). Before pacing, epi-
nephrine administration resulted in an approximate 30% to
85% increase in cardiac contractility, as measured by
changes in cardiac output (Table 1). Administration of epi-
nephrine failed to restore any of the measured indices of
ventricular performance in AdNull animals to levels equivalent
to those demonstrated by AdCUVEGF121.1 animals in the
resting state. Similarly, epinephrine administration resulted in a
mean increase in cardiac output in AdCUVEGF121.1 ani-
mals that was nearly double that of the increase in cardiac
output noted after epinephrine administration in AdNull
animals (Table 1).
Discussion
Despite many recent advances in the treatment of coronary
artery disease, including the application of angioplasty and
coronary bypass surgery to treat discrete lesions in the large
epicardial vessels, treatment options for patients with end-
stage ischemic cardiomyopathy remain limited. Such pa-
tients characteristically have diffuse coronary disease that is
often not amenable to treatment with conventional method-
ologies. Alternative treatment strategies, such as cardiac
transplantation, implantation of an artificial assist device, or
multidrug pharmacotherapy remain limited by significant
associated morbidities and toxicities. Thus there remains a
significant need for effective alternative therapies for car-
diomyopathy.
Angiogenic therapy appears to offer promise as an ef-
fective means of enhancing the function of ischemic myo-
cardium by improving blood flow to ischemic tissues
through increased myocardial vascularization.8-12 In con-
trast, the treatment of heart failure with chronic inotropic
TABLE 1. Cardiac output (L/min)
Rest Stress
AdNull AdCUVEGF121.1 AdNull AdCUVEGF121.1
Initial operation 1.4 0.4 2.2 0.9 2.6 0.8 4.0 1.6
Before pacing* 3.1 1.2 4.0 1.0 4.1 2.1 5.5 2.3
Days after pacing
0 3.3 1.5 3.8 1.2 3.3 1.3 4.8 1.6
7 2.7 0.7 4.3 1.1 3.4 0.6 5.7 1.9
14 1.8 0.3 3.8 1.1 2.5 0.6 5.0 1.4
21 1.0 0.3† 3.3 1.1 1.7 0.4 5.0 1.6
*Seven-day recovery period provided after the initial operation.
†P  .02 compared with baseline values.
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therapy has been associated with excessive mortality, pos-
sibly because this strategy may exacerbate preexistent isch-
emia.18
Evidence supporting the ability of growth factor admin-
istration to induce therapeutic angiogenesis has been pro-
vided by a wide variety of animal studies and a limited
number of early clinical trials.8-12,19-30 Gene therapy,
whereby the angiogenic agent is transferred to the myocar-
dium by means of a viral or plasmid vector as the cDNA for
the corresponding protein angiogen, is a promising delivery
strategy for angiogenic therapy.19 In the present study we
demonstrate that adenoviral-mediated transfer of VEGF 121
as an angiogenic mediator appears to minimize the devel-
opment of, and speed recovery from, ventricular dysfunc-
tion induced by rapid ventricular pacing. The findings of the
present study suggest that this intervention may represent an
effective treatment for cardiomyopathy.
Enhancement of myocardial performance after delivery of
the AdCUVEGF121.1 vector was demonstrated by means
of both echocardiographic and sonomicrometric assessment
of ventricular function, by using both global and regional
analyses. In comparison with prior studies demonstrating
that angiogenic therapy improves regional myocardial per-
fusion and function,8-10,20-22 angiogenic therapy in the
present study was used to treat global dysfunction and is
thus more relevant for the treatment of ischemic cardiomy-
opathy. In contrast to the 2 previous studies assessing the
treatment of global dysfunction with intracoronary delivery
of a growth factor,11,31 the present study demonstrates the
efficacy of an intramyocardial delivery technique. This ap-
proach takes advantage of the potentially beneficial local-
izing effects of intramyocardial delivery9,32 and suggests
that such a strategy is a viable means of homogeneously
enhancing global function, despite the use of multiple, iso-
lated injections.
Several limitations of this study must be addressed. First,
we did not specifically document the induction of angiogen-
esis in the current study, although clear evidence of en-
hanced vascularization, perfusion, function, or a combina-
tion thereof has been previously established after
myocardial delivery of angiogenic therapy,8-12,24,26,27,33,34
including our recent demonstration of enhanced myocardial
perfusion after AdCUVEGF121.1 delivery in the nonisch-
emic rabbit myocardium (G. F. Rahman, unpublished ob-
servations). Although it is possible that nonangiogenic ef-
fects of VEGF, such as vasodilator or cytoprotective
properties,12 may have played a role in the hemodynamic
changes noted in this study, the pharmacokinetics of ade-
novirus delivery, whereby transgene expression beyond 2
weeks is negligible,9,32 suggest that this alternative mecha-
nism is unlikely.
A second limitation is that the rapid ventricular pacing
model we used does not duplicate the diffuse coronary
occlusions and multiple myocardial infarctions typically
associated with ischemic cardiomyopathy in the clinical
setting. Myocardial ischemia in our model is likely induced
by excessive myocardial demand induced by rapid pacing
rather than the limited perfusion-blood supply associated
with coronary disease.34 The relevance of such a supply-
demand mismatch as a basis for ischemic cardiomyopathy
has been previously established, specifically in the porcine
model, in which collateral vessel formation remains limit-
ed.13,14,35 Evidence supporting the use of this preparation as
a relevant model of cardiomyopathy is further suggested in
the present study by the blunted response to epinephrine
observed in the AdNull-treated animals, which is consistent
with the -adrenergic downregulation characteristic of a
cardiomyopathic state.13,14,36 Furthermore, demonstration of
decreased ventricular function in naive animals paced with-
out vector administration suggests that this effect is the
direct result of pacing rather than a toxic effect of vector
administration. Given these considerations, it seems plausi-
ble that angiogenic therapy is effective in this model be-
cause of its ability to enhance myocardial blood supply
through increased vascularization.
In conclusion, we demonstrate that adenovirus-mediated
transfer of VEGF 121 in a porcine model of myocardial
dysfunction helps to preserve ventricular function and speed
recovery of myocardial contractility after rapid ventricular
pacing. This form of gene therapy may be useful for the
treatment of ischemic cardiomyopathy clinically.
We thank Barbara Cushing for editorial assistance and Tony
Davis for veterinary support.
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